• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
LTP
Click for more information
5.56% 25.5¢

LTR PHARMA LIMITED

Market Cap $17.95M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

LTR Pharma Limited is an Australia-based clinical-stage biopharmaceutical company. The... LTR Pharma Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on holistically improving men’s health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction (ED). Its lead product SPONTAN is set apart from existing ED therapies by its mechanism of action-intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work in 10 minutes or less. SPONTAN (SDS-089) is a novel intranasal drug (PDE5) delivery platform for Erectile Dysfunction. More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
LTP
Ann: Notification regarding unquoted securities - LTP 		18/04/24 0 226
18/04/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  226 
LTP
The Trials 		18/04/24 17 5.1K
18/04/24 Last post  The Stripester Comments Created with Sketch.  17  Views Created with Sketch.  5.1K 
LTP
Ann: Final Patients dosed in SPONTAN pivotal study 		05/04/24 10 4.4K
05/04/24 Last post  JackBNimble Comments Created with Sketch.  10  Views Created with Sketch.  4.4K 
LTP
Ann: Investor Presentation 		21/03/24 11 2.9K
21/03/24 Last post  UndergroundTrader Comments Created with Sketch.  11  Views Created with Sketch.  2.9K 
LTP
Ann: First patients dosed in SPONTAN pivotal study 		20/03/24 7 1.6K
20/03/24 Last post  Leroy23 Comments Created with Sketch.  7  Views Created with Sketch.  1.6K 
LTP
Ann: Recruitment commences for SPONTAN Clinical Study 		18/03/24 4 1.4K
18/03/24 Last post  Rorbag Comments Created with Sketch.  4  Views Created with Sketch.  1.4K 
LTP
Ann: LTR Pharma to List on the ASX
2 3
06/03/24 136 43K
06/03/24 Last post  toby10 Comments Created with Sketch.  136  Views Created with Sketch.  43K 
LTP
Ann: Appendix 4D and Half Yearly Report 		28/02/24 0 344
28/02/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  344 

See All Discussions arrow Created with Sketch.

Timeline

Notification regarding unquoted securities - LTP
18 Apr 16:59
 
Final Patients dosed in SPONTAN pivotal study
25 Mar 09:05
 
First patients dosed in SPONTAN pivotal study
19 Mar 08:45
 
Investor Presentation
18 Mar 08:32
 
Appendix 4D and Half Yearly Report
28 Feb 08:10
 
Recruitment commences for SPONTAN Clinical Study
19 Feb 08:11
 
View More arrow Created with Sketch.

Featured News

CC9 Chariot ends quarter charged up on lithium find in Wyoming
right-arrow Created with Sketch.
RCE Recce wins safety board approval to dose 4g in R327 UTI infusion trial
right-arrow Created with Sketch.
RDN Raiden's key target areas found drill ready in cultural heritage survey
right-arrow Created with Sketch.
ASM Aust Strategic sees Canada join US in possible funding push for Dubbo
right-arrow Created with Sketch.
NCK Nick Scali moves into the UK market through Fabb Furniture acquisition
right-arrow Created with Sketch.
BHP BHP confirms £31.1B takeover bid for Anglo American
right-arrow Created with Sketch.
(20min delay)
Last
25.5¢ 		Change
-0.015(5.56%) 		Mkt cap ! $17.95M
Open High Low Value Volume
27.0¢ 27.0¢ 25.5¢ $64.12K 246.7K

Buyers (Bids)

No. Vol. Price($)
1 5275 25.5¢
 

Sellers (Offers)

Price($) Vol. No.
26.0¢ 13714 1
View Market Depth
Last trade - 15.48pm 26/04/2024 (20 minute delay) ?
Last
25.5¢ 		  Change
-0.015 ( 5.56 %)
Open High Low Volume
25.5¢ 26.0¢ 25.5¢ 60224
Last updated 15.48pm 26/04/2024 ?
LTP (ASX) Chart

Top Stories

Week 17 Wrap: BHP-Anglo deal helps push down ASX; US data of concern but AI bulls happy

The big thematics and headlines that drove the ASX this week, plus, the headlines I think investors ought to be keeping eyes on.
Crypto world awaits overnight Bitcoin halving event The four-yearly Bitcoin halving is set to happen in the early hours of tomorrow morning (Saturday, April 20) - it's an event that industry leader Swyftx likened to 'the Olympic Games for the crypto industry'.
Recce Pharmaceuticals up 6% on new antibiotic production milestone Recce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch of its new antibiotic RECCE 327 (R327) under Good Manufacturing Practises (GMP) standards.
BHP confirms £31.1B takeover bid for Anglo American BHP HAS confirmed its offer to takeover fellow mining giant Anglo American plc, following press speculation of a potential deal.which had unsettled shareholder groups and financial firms in London, and provoked criticism from a South African government minister.
Lithium Universe reveals plan to fill a 'gap' in the North American market Lithium Universe has flagged its Québec Lithium Processing Hub in Canada as a key producer of battery-grade lithium to the North American market..

Featured News

NEWS Recharged Prospects: ‘Watts’ on the horizon for copper & lithium
right-arrow Created with Sketch.
CC9 Chariot ends quarter charged up on lithium find in Wyoming
right-arrow Created with Sketch.
BHP BHP confirms £31.1B takeover bid for Anglo American
right-arrow Created with Sketch.
RCE Recce wins safety board approval to dose 4g in R327 UTI infusion trial
right-arrow Created with Sketch.
RDN Raiden's key target areas found drill ready in cultural heritage survey
right-arrow Created with Sketch.
NCK Nick Scali moves into the UK market through Fabb Furniture acquisition
right-arrow Created with Sketch.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.